Slowly but surely. This is how the Strategic Project for Recovery and Economic Transformation (Perte) for Vanguardia Health is progressing in Spain, a project that aims to outline healthcare for the coming years, responding to the needs of patients and professionals after the outbreak of the Covid-19 pandemic.
Vanguardia’s Perte para la Salud initially contemplated an investment of more than one billion euros between 2021 and 2023, as announced in mid-November 2021 by Prime Minister, Pedro Sánchez, at a press conference at La Moncloa.
However, the Minister of Science and Innovation, Diana Morant, and the Minister of Health, Carolina Darias, announced last November, at the second meeting of the Alianza Salud de Vanguardia, that the Government will increase public investment by 50% in Perte, from €982 million initially planned to at least €1.5 billion.
The plan that will be implemented by the Spanish administrations and companies in the sector aims to promote the development of advanced therapies and other innovative or emerging drugs and facilitate their transfer to clinical practice, promote the equitable implementation of personalized precision medicine in the National System of Health (SNS), carry out an innovative data system that allows the collection, treatment, analysis and exploitation of data from different sources to improve prevention and diagnosis, as well as implement the digital transformation of health care.
Read more on the subject and find the latest financial news of the day with the Born2Invest mobile app.
Vanguardia’s Perte para la Salud initially contemplated an investment of more than €1 billion between 2021 and 2023
The Carlos III Health Institute (ISCIII) manages €177.4 million, which represents 18% of the public contribution to Perte. The current state of its actions represents a state of compliance of approximately 168 million euros, mostly from funds from the Mechanism for Recovery and Resilience (MRR), which represents 95% compliance. Among all its actions, the commitment of €29.5 million in the call for Personalized Precision Medicine of 2021 stands out.
On July 13th, 2022, the new call for the granting of subsidies for the year to Personalized Precision Medicine Research Projects for €81.5 million was published. Likewise, in October the joint call between the ISCIII and the Center for Technological Development and Innovation (Cdti) for Innovations in Precision Medicine and Advanced Therapies for €55 million was published.
On the other hand, the actions carried out by the ISCIII platforms (€18 million already released in 2022) that promote innovation capacities in health technologies and the implementation of precision medicine as instruments that contribute to the sustainability of the SNS, along with the 2021 call for independent clinical research, in which €15 million are committed.
As regards the Cdti, the institution manages €184.54 million, which represents 19% of the public contribution to the Perte. Specifically, the entity has carried out actions related to the objective of promoting the development of advanced therapies and other innovative drugs for a value of €136.87 million, which represents 74% compliance. Among the measures, the missions in advanced therapies, direct investments in innovative companies in the biohealth field to strengthen their capacities, and specialized technology transfer funds in the biohealth field through the Innvierte program and the ISCIII-Cdti call stand out.
The measures include missions in advanced therapies and direct investments in innovative companies
The Ministry of Science, through the General Secretariat for Research, leads the execution of the complementary plans for research, development, and innovation (R+D+I) in biotechnology applied to health, with €37.27 million.
These plans are configured through co-investment with the autonomous communities. Specifically, Catalonia, Castilla-La Mancha, Extremadura, the Basque Country, Galicia, Andalusia, and Aragon participate in the Biotechnology Program applied to health. The general framework for the implementation of this program was approved by the Scientific, Technological and Innovation Policy Council, which approved a total initial budget of €32 million, of which €19.38 million were contributed by the Ministry of Science and €17.89 million, by region.
Focus on primary care
For the Digital Transformation of Health Care in Primary Care action, seven working groups have been created, each one led by one or more autonomous communities, which have defined 16 lines of action and a total of 152 projects, of which 113 initiatives are collaborative projects, with a total allocated budget of €179.3 million. The projects are focused on the following areas: digital healthcare center, personalized attention, and digital transformation of healthcare activity support services.
The projects in these areas will improve clinical activity through digital technologies and information systems that facilitate their planning and execution; the registration, integration, recovery, and analysis of data, the interconnection of professional teams, in general, will increase the efficiency and quality of clinical practice, promoting the extension and interoperability of the digital medical record. In addition, all the projects that make up this plan will contribute to and benefit from the National Health Data Space, which will federate the health data spaces of the communities and will in turn be integrated as one more node in the European Health Data Space. and will facilitate the progress of the SNS toward personalized and preventive medicine.
Contribution to GDP
It is estimated that globally the Vanguard Health Department will generate a contribution to the Gross Domestic Product (GDP) of up to €4.34 billion and the creation of up to 12,688 new jobs. From the point of view of health impacts, a minimum saving of 15% is expected in disability-adjusted life years for each of the pathologies linked to the actions of this Part and a 30% decrease in inter-territorial differences in years of healthy life after the age of 65.
With the Health Perte, the Government hopes that biomedical innovation will consolidate as an engine for changing the production model, promoting quality employment, economic development, and strengthening the industrial fabric and that the SNS will be a world benchmark in medicine of precision through the massive, intelligent and health-oriented use of different data sources (biological, environmental, functional, behavioral and others) and that public-private collaboration is a tool of daily use. In addition, the Perte intends to deploy instruments and structures that ensure collaboration and coordination between the scientific fabric and the Spanish business fabric.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Jazz Pharmaceuticals’ Leukemia Drug Receives European Commission Approval
Jazz Pharmaceuticals is a biopharmaceutical company dedicated to the development of drugs in neuroscience and oncology. Founded in 2003 in...
Citi Announced a $6 Million Loan to Sempli for SME financing
The credit granted by Citi was given in partnership with high-impact investors and multilateral development organizations. They all seek to...
How Will the Price of Ripple and Cardano Develop in the Next Few Days
The BOLL indicator shows no specific pattern and denotes the support price of $0.4969 and the resistance price of $0.5059,...
RADEEF: a 182 Million Dirham Plan to Combat Flooding in Morocco
RADEEF is also planning major expansion projects. Firstly, it plans to launch work on extending the wastewater treatment plant. The...
How Institutional Investors Feel About Impact Investing
Investors continue to face greenwashing when implementing impact investing. Among their key concerns are misleading or exaggerated impact claims (60%),...
Africa2 weeks ago
Bobo-Dioulasso Has a Regional Branch of the Burkinabe Social Development Fund
Crowdfunding5 days ago
Biova Project Launched an Equity Crowdfunding Campaign on Mamacrowd
Business2 weeks ago
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [CamSoda Affiliates Review]
Africa4 hours ago
RADEEF: a 182 Million Dirham Plan to Combat Flooding in Morocco